DIVISLAB's weekly performance was lackluster, with a return of -1.62% and a Sharpe Ratio of -0.21, indicating poor risk-adjusted returns. The stock's volatility was high at 29.37%, making it a risky investment this week. Compared to its peers, DIVISLAB outperformed SUNPHARMA and CIPLA but underperformed DRREDDY. Overall, the stock's high volatility and negative returns make it a cautious investment opportunity.

[Volatility: 29.37%]